Treatment of chronic hepatitis B and the implications of viral resistance to therapy

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 2, 2008, Pages 191-199

  Mauss, Stefan ^a   Wedemeyer, Heiner ^b  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Drug resistance; Hepatitis B; Therapy; Vaccine escape

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; MIXED INFECTION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; RELAPSE; REVIEW; VACCINATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; HEPATITIS B VIRUS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 45549103253     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.2.191     Document Type: Review

References (64)

1. Chen CJ, Yang HI, So J et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
2. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL- HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (3), 678-686 (2006).
3. Tang B, Kruger VM, Chen G et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J. Med. Virol. 72(1), 35-40 (2004).
4. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann. Intern. Med. 135, 759-768 (2001).
5. Yang HI, Lu SN, Liaw YF et al.; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347, 168-174 (2002).
6. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato E Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 57(1), 84-90 (2008).
7. Thomas HC. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J. Hepatol. 47(4), 588-597 (2007).
8. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45(2), 507-539 (2007).
9. Cornberg M, Protzer U, Dollinger MM et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: upgrade of the guideline. Z. Gastroenterol. 45(6), 525-574 (2007).
10. Liaw YF, Sung JJ, Chow WC et al.; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351(15), 1521-1531 (2004).
11. Di Marco V, Marzano A, Lampertico P et al.; Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40(4), 883-891 (2004).
12. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon α for chronic hepatitis B. N. Engl. J. Med. 334(22), 1422-1427 (1996).
13. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology 44, 548A (2006).
14. 2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682-2695 (2005).
15. Erhardt A, Blondin D, Hauck K et al. Response to interferon a is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54(7), 1009-1013 (2005).
16. Hadziyannis SJ, Sevastianos V, Rapti I et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B. Hepatology 44, 213A (2006).
17. 2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351(12), 1206-1217 (2004).
18. 2a (40kD) ± lamivudine: 3-year follow-up results. Presented at: 42nd Annual Meeting of the European Association for the Study of the Liver 2007. Barcelona, Spain, 11-15 April 2007 (Abstract 53).
19. Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 44, 222A (2006).
20. Lai CL, Leung N, Teo EK et al.; Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2), 528-536 (2005).
21. Marcellin P, Chang TT Lim SG et al.; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348(9), 808-816 (2003).
22. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43(6), 1385-1391 (2006).
23. Westland C, Delaney W 4th, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in Phase III studies of adefovir dipivoxil 1. Gastroenterology 125(1), 107-116 (2003).
24. Lampertico P, Marzano A, Levriero M et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative hepatitis B. Hepatology 44, 693A (2006).
25. Lampertico, P. Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 133(5), 1445-1451 (2007).
26. Chang T, Gish R, De Man R. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010 (2006).
27. Lai C, Shouval D, Lok A. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011-1020 (2006).
28. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51(3), 902-911 (2007).
29. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6), 1656-1665 (2006).
30. Reijnders JG, De Man RA, Pas SD, Schutten M, Janssen HL. Entecavir: a rescue therapy for chronic hepatitis B patients with a limited virological response to adefovir? Hepatology 46(4 Suppl. 1), 660A (2007) (Abstract 951).
31. Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 16, 2352-2354 (2002).
32. Nelson M, Portsmouth S, Stebbing J. An open-label study of tenofisvir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 17, F7-F10 (2003).
33. Van Bommel F, Wunsche T, Mauss S. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40, 1421-1425 (2004).
34. Ristig M, Crippin J, Aberg J. Tenofovir disoproxil fumarate for chronic hepatitis B in HIV-coinfected individuals for whom interferon a and lamivudine therapy have failed. J. Infect. Dis. 186, 1844-1847 (2002).
35. Benhamou Y, Fleury H, Trimoulet P. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV- infected patients. Hepatology 43, 548-555 (2006).
36. Heathcote EJ, Gane E, DeMan R et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US- 174-0103. Hepatology 46(4 Suppl. 1), 861A (2007) (Abstract LB6).
37. Marcellin P, Buti M, Krastev Z et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. Hepatology 46(4 Suppl.1), 290A (2007) (Abstract LB2).
38. Schmutz G, Nelson M, Lutz T et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 20(15), 1951-1954 (2006).
39. Van Boemmel F, Zoellner B, Moeller B et al. Is tenofovir effective in treatment of adefovir resistant hepatitis B virus infections? Hepatology 44, 567A (2006).
40. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 48(3), 391-398 (2008).
41. Sung JJ, Lai JY, Zeuzem S et al. A randomised double-blind Phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week 52 analysis. J. Hepatol. 38(Suppl. 2), 25-26 (2003).
42. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 9(5), 679-693 (2004).
43. Lampertico P, Vigano M, Manenti E et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42, 1414-1419 (2005).
44. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356, 2614-2621 (2007).
45. Sheldon JA, Corral A, Rodés B et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 19(17), 2036-2038 (2005).
46. Delaugerre C, Marcelin AG, Thibault V et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated fbr HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother. 46(5), 1586-1588 (2008).
47. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30(5), 1302-1306 (1999).
48. Matthews GV, Bartholomeusz A, Locamini S et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20(6), 863-870 (2006).
49. Sheldon J, Ramos B, Garcia-Samaniego J et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/ HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J. Acquir. Immune Defic. Syndr. 46(3), 279-282 (2007).
50. Lin CI, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 54 (1), 152-161 (2005).
51. Lai CL, Gane E, Liaw YF et al.; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357(25), 2576-2588 (2007).
52. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256-1263 (1999).
53. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32, 847-851 (2000).
54. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352, 2673-2681 (2005).
55. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006).
56. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800-807 (2003).
57. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-68 (1998).
58. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of. YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687-696 (2003).
59. Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivadine. Hepatology 44, 222A (2006).
60. Lai CL, Gane E, Liaw YF et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international Phase III globe trial. Hepatology 42, 748A (2005).
61. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43, 1385-1391 (2006).
62. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714-1722 (2003).
63. Westland CE, Yang H, Delaney WE et al. Week 48 resistance surveillance in two Phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38, 96-103 (2003).
64. Colonno RJ, Rose RE, Pokornowski K et al. Assessment at three years show high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 44, 229A-230A (2003).